Significantly, median sensitivity in the RB1-defective group was comparable to that of the pancreatic cancer line CAPAN1, known for profound PARPi sensitivity due to defective BRCA225 that we included to benchmark clinically relevant response levels. This evidence concerns the gene RB1 and familial pancreatic carcinoma.